2025/01/22 by Sérgio Parente Filho, Jacqueline Holanda de Souza, Germana Franck de Souza Bastos Rocha +7 · 1 voice
Biochemistry, Genetics and Molecular Biology · Medicine · #Multiple Myeloma Research and Treatments #Protein Degradation and Inhibitors
paper · pdf · doi:10.46765/2675-374x.2025v6n1p249
openalex publication_date 2025/01/22 · openalex created_date 2025/10/10 · openalex updated_date 2026/06/26
Multiple Myeloma (MM) is a mature hematological neoplasm characterized by histological infiltration (bone marrow and/or extramedullary plasmacytomas) by clonal plasma cells and the presence of one or more defining events, including anemia, renal impairment, osteolytic lesions, and hypercalcemia. The management of MM has drammaticaly evolved over the past few years. However, new drugs are not available in the Brazilian public health service and treatment is still a challenge, especially in the relapsed/refractory setting. We herein summarize the updates in MM management and make recommendations for care in an optimal scenario and in the Brazilian public health service.